TABLE OF CONTENTS
Volume 36, Issue 11 (December (1) 2005)
Conditioning Regimens |
Stem Cell Procurement |
Allografting |
Autografting |
Post-Transplant Events |
Graft-Versus-Tumor Effects |
Graft-Versus-Host Disease |
Correspondence
Review
Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: a changing paradigm FREE
A Y H Leung, K-Y Yuen and Y-L Kwong
Bone Marrow Transplant 36: 929-937; advance online publication, September 26, 2005; doi:10.1038/sj.bmt.1705139
Conditioning Regimens
High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy FREE
D Valteau-Couanet, B Fillipini, E Benhamou, J Grill, C Kalifa, D Couanet, J L Habrand and O Hartmann
Bone Marrow Transplant 36: 939-945; advance online publication, September 26, 2005; doi:10.1038/sj.bmt.1705162
Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party FREE
A Bacigalupo, F Locatelli, E Lanino, J Marsh, G Socié, S Maury, A Prete, A Locasciulli, S Cesaro and J Passweg for the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (SAA WP-EBMT)
Bone Marrow Transplant 36: 947-950; advance online publication, October 3, 2005; doi:10.1038/sj.bmt.1705165
Stem Cell Procurement
Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma FREE
A Corso, S Mangiacavalli, A Nosari, C Castagnola, P Zappasodi, A M Cafro, C Astori, M Bonfichi, M Varettoni, C Rusconi, D Troletti, C Pascutto, E Morra and M Lazzarino on behalf of the HOST group
Bone Marrow Transplant 36: 951-954; advance online publication, September 26, 2005; doi:10.1038/sj.bmt.1705166
Allografting
Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma FREE
C Andreadis, S J Schuster, E A Chong, J Svoboda, S M Luger, D L Porter, D E Tsai, S D Nasta, R L Elstrom, S C Goldstein, L H Downs, P A Mangan, K A Cunningham, K A Hummel, P A Gimotty, D L Siegel, E Glatstein and E A Stadtmauer
Bone Marrow Transplant 36: 955-961; advance online publication, October 3, 2005; doi:10.1038/sj.bmt.1705178
Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma FREE
S Gerull, M Goerner, A Benner, U Hegenbart, U Klein, H Schaefer, H Goldschmidt and A D Ho
Bone Marrow Transplant 36: 963-969; advance online publication, September 26, 2005; doi:10.1038/sj.bmt.1705161
Unrelated donor stem cell transplantation in adult patients with thalassemia FREE
G La Nasa, G Caocci, F Argiolu, C Giardini, F Locatelli, A Vacca, M G Orofino, E Piras, M C Addari, A Ledda and L Contu
Bone Marrow Transplant 36: 971-975; advance online publication, October 3, 2005; doi:10.1038/sj.bmt.1705173
Autografting
FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation FREE
G Yoshimoto, K Nagafuji, T Miyamoto, N Kinukawa, K Takase, T Eto, K Kato, S Hayashi, T Kamimura, Y Ohno, S Taniguchi and M Harada
Bone Marrow Transplant 36: 977-983; advance online publication, September 26, 2005; doi:10.1038/sj.bmt.1705169
Post-Transplant Events
Significance of eosinophilia after stem cell transplantation as a possible prognostic marker for favorable outcome FREE
T Sato, R Kobayashi, M Nakajima, A Iguchi and T Ariga
Bone Marrow Transplant 36: 985-991; advance online publication, September 26, 2005; doi:10.1038/sj.bmt.1705168
Graft-Versus-Tumor Effects
Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants FREE
M T Martinez, Ch Bucher, G Stussi, D Heim, A Buser, D A Tsakiris, A Tichelli, A Gratwohl and J R Passweg
Bone Marrow Transplant 36: 993-1000; advance online publication, September 26, 2005; doi:10.1038/sj.bmt.1705160
Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath) FREE
G D Myers, R A Krance, H Weiss, I Kuehnle, G Demmler, H E Heslop and C M Bollard
Bone Marrow Transplant 36: 1001-1008; advance online publication, September 26, 2005; doi:10.1038/sj.bmt.1705164
Graft-Versus-Host Disease
Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation FREE
B N Savani, A Montero, R Kurlander, R Childs, N Hensel and A J Barrett
Bone Marrow Transplant 36: 1009-1015; advance online publication, October 3, 2005; doi:10.1038/sj.bmt.1705167
Correspondence
Resistance to pretransplant imatinib therapy may adversely affect the outcome of allogeneic stem cell transplantation in CML FREE
M Weisser, C Schmid, C Schoch, W Hiddemann and H J Kolb
Bone Marrow Transplant 36: 1017-1018; advance online publication, September 26, 2005; doi:10.1038/sj.bmt.1705172
Retinal and cerebral toxoplasmosis following nonmyeloablative stem cell transplant for chronic lymphocytic leukaemia FREE
M Power, E Vandenberghe, E Conneally, P V Browne, D Kilmartin, M O'Connor, N Sheehy and S McCann
Bone Marrow Transplant 36: 1019-1020; advance online publication, October 3, 2005; doi:10.1038/sj.bmt.1705177
